Home > Updates > Caraco: More on distribution of Eloxatin

Caraco: More on distribution of Eloxatin

Here are some numbers on what the distribution of the generic Eloxatin could amount for Caraco:

“If Sun launches at risk, our conservative assumptions suggest Sun could easily generate about $50 million in profits during the exclusivity window,” Macquarie analysts Abhishek Singhal and Gautam Duggad wrote in a report.

For ANDAs in the exclusivity window, Caraco gets 10% of the profits. The costs for Caraco should be minimal as Sun Pharma is responsible for production of the drugs. At 10% of the estimated $50 million, Caraco could end up netting $4-5 million. This is over a 6 month period. This should make Caraco break even or even cash positive.

Advertisements
Categories: Updates
  1. No comments yet.
  1. No trackbacks yet.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: